US HHS Warns HMOs On Treatment Option Gags

16 December 1996

The US Department of Health and Human Services has told over 300 health maintenance organizations nationwide that HMOs and other health plans may not limit what doctors tell Medicare patients about treatment options. Federal health officials plan a similar policy for HMOs serving Medicaid patients, the New York Times notes.

Additionally, Congress is soon to consider a bill to ban these limits in private insurance as well as government programs. Doctors have said these gag clauses discourage them from telling patients about treatment options not covered by HMOs; these other options often carry expensive price tags. Because of last year's public debate over gag clauses, some HMOs have already dropped or modified them.

The HHS statement said Medicare HMO patients are entitled to all benefits available in the standard Medicare program, one of which was advice from doctors on "medically necessary treatment options." Any contract which limits a doctor's ability to advise a Medicare beneficiary is a violation of the federal Medicare law. A doctor caring for a Medicare patient "may not be limited in counseling or advising the beneficiary" about treatment options that may be appropriate for the patient's condition or disease; contracts which limit that ability "are a violation of the law."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight